Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in children with hemophagocytic lymphohistiocytosis
ChiCTR2000031702Phase 2Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Children's Hospital. Primary endpoint: Overall response rate. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2000031702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031702.